| 标题 |
SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes
在无糖尿病肥胖个体中进行的索马鲁肽和蛋白尿减少试验
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供，该求助的时间将会延长，查看原因？
|
| 其它 | Brief Summary Study to assess the effects of weekly subcutaneous administration of the GLP1-RA semaglutide 2.4mg on kidney function parameters in obese/overweight individuals at high risk of CKD progression. Detailed Description Glucagon Like Peptide 1 Receptor Agonist (GLP1-RA) therapies have been introduced as antidiabetic drugs. In addition, GLP1-RA therapies reduce body weight, in patients with and without diabetes, without inducing hypoglycemia. Moreover, GLP1-RA reduce albuminuria in patients with type 2 diabetes, and liraglutide and semaglutide have been shown to improve various risk markers of CKD progression in non-diabetic obese individuals. It is therefore likely that these agents delay progression of kidney function decline in high risk obese/overweight, non-diabetic individuals. |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)
Nole
cdercder
XX
Dong021
Kao
GingerF
无极微光
Logan
null
独特的项链
谪仙
mmyhn
有人
W sir
heekkll
好好
xuz
a7662888
神勇映雁
OK
皖公网安备34019202002308
